Related Factors Affecting Long-term Prognosis of AML Children with Positive RUNX1-RUNX1T1.
10.7534/j.issn.1009-2137.2019.06.010
- Author:
Guang-Ying TENG
1
;
Wen-Jing QU
1
;
Kun ZHANG
2
Author Information
1. Department of Pediatrics, The Second Maternal and Child Health Center of Jinan, Jinan 271100, Shandong Province, China.
2. Department of Pediatric Hematology, Qilu Children's Hospital, Shandong University, Jinan 250022, Shandong Province, China,E-mail: lwtgy1120@163.com.
- Publication Type:Journal Article
- MeSH:
Child;
Core Binding Factor Alpha 2 Subunit;
Humans;
Leukemia, Myeloid, Acute;
Oncogene Proteins, Fusion;
Prognosis;
RUNX1 Translocation Partner 1 Protein;
Retrospective Studies
- From:
Journal of Experimental Hematology
2019;27(6):1767-1773
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the related factors affecting the long-term prognosis of acute myeloid leukemia (AML) children with positive RUNX1-RUNX1T1.
METHODS:The clinical data of 63 chlidren with positive RUNX1-RUNX1T1 AML treated by BCH-AML 05 regimen in our hospital from January 2010 to December 2015 were collected and analyzed retrospectively. The level of RUNX1-RUNX1T1 was detected at the time of initial diagnosis (T), after the first induction treatment (T), after the second induction treatment (T), after the first consolidation treatment (T), after the second consolidation treatment (T) and after the third consolidation treatment (T). According to the fusion transcript levels of RUNX1-RUNX1T1 the AML children were divided into low-expression group and high-expression group; the threshold values for grouping were 10 copies/10 β-glucuronidase (GUS), 10 copies/10 GUS, 10 copies/10 GUS, 10 copies/10 GUS, 1 copies/10 GUS and 0 copies respectively. The gained data were enrolled in the statistical analysis.
RESULTS:23 cases of 63 children died during the follow-up period, and the median follow-up time of the remaining 40 children were 30.04 (11-60) months. There were statistically significant differences in CD15 positive rate between low-expression group and high-expression group (P<0.05), however, there were no statistically significant differences in sex, age, FAB typing, platelet (Plt) count, hemoglobin (Hb) and white blood cell (WBC) count and the ratio of bone marrow immature cells at T2 between the two groups (P>0.05). Univariate analysis showed that sex, Plt counts at T and fusion transcript levels at T, T and T correlated with the 5-year overall survival rate (P<0.05). Multivariate analysis showed that fusion transcript level >10 copies/10 GUS at T was an independent risk factor for 5-year overall survival rate (HR=2.13, 95%CI: 1.04-7.78)(P<0.05).
CONCLUSION:The fusion transcript level after the first induction therapy in RUNX1-RUNX1T1-positive AML children is an independent factor influencing the long-term prognosis.
